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before inclusion diagnosed -histological conﬁrmed-, in any pro-
gression state and already treated or under treatment. All diag-
nosis methods used and health care utilization resources were
collected, expressed their cost as 2007 €. RESULTS: A total of
1404 patients (pts) have been evaluated (mean age: 70.2  8.6).
Nine percent of pts were diagnosed by screening PSA programs,
50% by either general practitioner or specialist and 42% by
urologist. Screening programs were performed signiﬁcantly more
frequent in younger pts (<45 años), with University degree, famil-
iar precedent and workers in assets. Three consecutive phases
on diagnosis process were identiﬁed: 1)First PSA origin,
2)Conﬁrmation/Differentiation and 3)Extension study. 1st step
included: opportunistic screening, physician recognition, com-
plete med tests and PSA; 2nd: Transrectal ultrasonografy, pros-
tate biopsy and Gleason; & 3rd: Computed tomography (CT)
magnetic resonance imaging (MRI), urography, isotopic bone
scan (IBS), abdominal sonography and PET. Any additional step/
test were added based on clinical criteria. Based on International
Guidelines: 77.6% of IBS were well done vs. 43.8% not recom-
mended; CT 64.8% vs 48.8% not. Final total cost, in case all
steps/procedures were done, was €2339.95  680.14, and for
each step: 1st €246.47  0.0€, 2nd €1650.17  587.27 and 3rd
€511.43  313.42. CONCLUSIONS: Prostate cancer diagnosis
methods in Spain are widely variable. Gold standards are not
followed strictly. Potential savings for Spanish NHS could be
gather if additional not recommended test were not done increas-
ing adherenc to gold standards.
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NEW OPPORTUNITIES FOR DRUG OUTCOMES RESEARCH IN
CANCER PATIENTS: VALIDATION OFTHE LINKAGE OFTHE
EINDHOVEN CANCER REGISTRY ANDTHE PHARMO RECORD
LINKAGE SYSTEM
Sukel MPP1,Van de Poll-Franse LV2, Coebergh JWW2,
Herings RMC1
1PHARMO Institute, Utrecht,The Netherlands, 2Eindhoven Cancer
Registry, Eindhoven,The Netherlands
OBJECTIVES: To validate the linkage of the Eindhoven Cancer
Registry (ECR) and the PHARMO Record Linkage System
(PHARMO RLS). METHODS: The ECR records data on all
newly diagnosed cancer patients in the Southeastern Netherlands
whereas the PHARMO RLS includes data on e.g. in- and outpa-
tient drug use, hospital morbidity and clinical laboratory. The
overlapping catchment area of both registries includes approxi-
mately 1 million inhabitants. The linkage of the ECR and
PHARMO RLS was performed with the PHARMO Probabilistic
Record Linkage Engine. After pairing records from both regis-
tries on date of birth and gender, a linkage weight was calculated,
based on ﬁrst initial, ﬁrst letter last name and 4-digit zip code.
The suggested threshold weight was used to divide pairs in
correct and incorrect linked pairs, i.e. pairs that include infor-
mation from both registries that point to the same or to different
patients, respectively. The sensitivity and speciﬁcity of this
linkage process was validated using a random subset of linked
and non-linked patients which were compared with a ‘gold-
standard’ using detailed personal information from the original
data sources. RESULTS: Of N = 58,197 cancer patients from the
ECR living in the PHARMO catchment area, N = 47,012(81%)
were linked to a patient from the PHARMO RLS and regarded as
being the same patient. The validated subset consisted of 2887
true positive linked pairs and the linkage of this subset yielded a
speciﬁcity of 99.5% (95% CI: 99.4%–99.7%) and a sensitivity
of 98.3% (95% CI: 97.7%–98.7%). CONCLUSIONS: The
linkage of the ECR and the PHARMO RLS is highly sensitive
and speciﬁc. The new linked database includes of more than 80%
of the cancer patients detailed information on in- and outpatient
drug treatment, co-medication, co-morbidity and other clinical
and economical details and can be used as a new source for
outcomes research in cancer treatment and post-marketing sur-
veillance of drug-induced cancer.
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DEVELOPMENT OF AN INTERACTIVE MODEL OF FINANCIAL
ACCESSTO CANCERTHERAPY
Lines LM1, Lang K1,Wallace JF2, Neumann PJ3, Friedman M4,
Menzin J1
1Boston Health Economics, Inc,Waltham, MA, USA, 2Genentech, Inc,
South San Francisco, CA, USA, 3Tufts Medical Center, Boston, MA,
USA, 4Boston Health Economics,Waltham, MA, USA
OBJECTIVES: Financial access to medical technologies in the
United States may be driven by many factors, including drug
costs, health insurance coverage, beneﬁt designs, and patients’
ability or willingness to pay for treatment. Studies evaluating
out-of-pocket costs for cancer treatment have been conducted;
however, no national models of ﬁnancial access currently exist.
METHODS: We developed a conceptual framework for an inter-
active model of ﬁnancial access to cancer therapy. To illustrate
the model’s operation, we applied it to treatment of
HER2+ breast cancer patients. The model traces the ﬂow of
patients along pathways of a decision tree. Beginning with the US
population, the model branches by sex, breast cancer or no
breast cancer, HER2+ or HER2- cancer, and insurance status.
Only patients in the HER2+ branch are followed forward
through the model. Patients are stratiﬁed by payor and beneﬁt
design, eligibility for patient assistance programs, and ability to
pay for treatment without spending more than a pre-speciﬁed
percentage of family income out-of-pocket. Data sources include
custom analyses of publicly available databases (to determine
incidence/prevalence and the annual income and expenditures of
breast cancer patients), clinical trial data on dosages, and
national survey data on the proportion of patients with different
beneﬁt designs. The user interface allows for unlimited variations
in key input parameters. RESULTS: Model outputs include a
series of graphs showing ﬁnancial access before and after adding
speciﬁc treatments, with and without support from patient assis-
tance programs. Results are presented by payor, age, and income.
Sensitivity analyses can be conducted to evaluate the robustness
of results. CONCLUSIONS: While it is difﬁcult to ascertain the
number of patients who are not receiving treatment because of
ﬁnancial barriers, it is possible to develop a model that appro-
priately considers the main drivers of ﬁnancial access to estimate
the impact of ﬁnancial barriers.
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DEALING WITH QUALITY OF LIFE MISSING DATA IN A
SINGLE ARM STUDY. COMPARISON OF MULTIPLE
IMPUTATION METHODS
Arnault A1, Ivanescu C2, van Engen A2, Peeters P1
1Quintiles Consulting, Levallois-Perret, France, 2Quintiles Consulting,
Hoofddorp,The Netherlands
OBJECTIVES: Assessment of Quality of Life (QoL), a Patient
Reported Outcome (PRO), has gained acceptance as a study
endpoint. An open-label, multicenter phase II, single arm oncol-
ogy study was conducted with a QoL endpoint aiming to assess
change of scores from baseline to 12-week or End of Study
(whichever occurred ﬁrst). This required the availability of the
baseline and at least one post-baseline assessment. Unfortunately,
missing data affects the validity of QoL assessment. A set of
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different techniques to deal with missing data was compared.
METHODS: The analysis addressed the global health status
scale (QL range [1;100]) of QLQ-C30, the EQ-5D utility index
(Utility range [0;1]) and Visual Analysis Scale (VAS range
[0;100]). Five multiple imputation (MI) techniques were carried
out with two softwares (SAS, IVEware) and compared with
Rubin’s efﬁciency: Monte-Carlo Markov Chain (MCMC),
Expectation-Maximization (EM), Regression (REG), Propensity
score (PROP) and Sequential regression (SEQ), using 5 simula-
tions per technique. RESULTS: Changes signiﬁcance varied
depending on the imputation technique. At baseline, mean scores
were: QL 0.73, EQ-5D index 63.4, and VAS 68. For QL score,
the change estimations were (mean [95%CI]): -1.699 [-3.322;
-0.076] (MCMC), -1.558 [-3.132; 0.015] (EM), -1.795
[-3.449; -0.141] (REG), -1.197 [-3.067, 0.673] (PROP),
-0.895 [-5.622; 3.832] (SEQ). For EQ-5D index, estimations
were: -0.020 [-0.042; 0.003] (MCMC), -0.018 [-0.043; 0.007]
(EM), -0.018 [-0.034; -0.002] (REG), -0.015 [-0.045; 0.014]
(PROP), -0.010 [-0.049; 0.030] (SEQ). VAS changes varied
from 0.019 (SEQ) to 0.791 (PROP), no change estimation was
signiﬁcant. Rubin’s efﬁciency was comprised between 88.32%
and 94.43% depending on score and technique. CONCLU-
SIONS: Results have to be carefully interpreted since they vary
according to the MI method. SEQ is the only method not assum-
ing a normal distribution of the data and consequently displays
large conﬁdence intervals. Nevertheless, multiple imputation is
told to be robust to normality. A sensitivity analysis is advised in
order to compare the different results.
PCN110
STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC
FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE
Mauer M, Coens C, Bottomley A
European Organisation for Research and Treatment of Cancer
(EORTC), Brussels, Belgium
OBJECTIVES: Whilst a number of systematic reviews (e.g.
Gotay et al in press) have been analyzing prognostic value of
patient-reported outcomes (PROs), including HRQOL, few have
focused on the statistical methods used. In this study, we
reviewed the statistical methods employed and proposed robust
statistical analysis for future PROs studies predicting survival of
cancer patients. METHODS: A total of 49 English articles were
selected from published reviews, conference abstracts, Medline
(1990–2008), various databases and discussions with colleagues
and reviewed during June to December 2007. Each article was
systematically examined for a key set of factors such as design
issues, selection of HRQOL factors, control for clinical factors
along with a detailed extraction of the statistical methods used
for analyzing HRQOL data. Once compiled, we identiﬁed good
practice and recommended approaches for future research.
RESULTS: Most HRQOL prognostic factor analyses, often
within clinical trials, are not deﬁned in protocols. In addition, a
detailed description of the statistical methodology and reporting
of the HRQOL results was often lacking in publications. Infor-
mation regarding sample size, handling missing data and the
veriﬁcation of the model assumptions varied considerably. Pre-
selection of HRQOL factors was not always done. A large
number of HRQOL factors increases the risk of selecting a factor
by chance and model over ﬁtting. In the model building strategy,
several approaches controlled for clinical factors in the analysis,
others allowed clinical factors replacement with (perhaps
slightly) more prognostic HRQOL factors. Model validation was
reported in nine studies. Measures of predictive accuracy were
computed in only seven studies. CONCLUSIONS: Undertaking
HRQOL prognostic factor analysis is a challenge. The priority is
validation and careful use of techniques and providing proof that
the addition of HRQOL indicators signiﬁcantly increases the





THE IMPACT OF INSULIN DETEMIR COMPAREDTO NEUTRAL
PROTAMINE HAGEDORN INSULIN ON LONG-TERM
DIABETES-RELATED COMPLICATIONS:A MODELING
ANALYSIS INTYPE 1 DIABETES PATIENTS IN BELGIUM,
FRANCE, GERMANY, ITALY AND SPAIN
Gschwend MH1,Aagren M2,Valentine WJ1
1IMS Health, Allschwil, Switzerland, 2Novo Nordisk A/S,Virum,
Denmark
OBJECTIVES: The aim of this analysis was to evaluate the time
to onset and long-term cumulative incidence of diabetes-related
complications in type 1 diabetes patients receiving either insulin
detemir or Neutral Protamine Hagedorn (NPH) insulin in com-
bination with mealtime insulin aspart in ﬁve countries (Belgium,
France, Germany, Italy and Spain). METHODS: A published and
validated computer simulation model of diabetes (CORE Diabe-
tes Model) was used to make long-term projections of clinical
outcomes, based on patient characteristics and treatment effects
from a 2-year, multi-national, open-label, randomized, con-
trolled trial. In the trial, insulin detemir was associated with
signiﬁcant improvements in glycemic control after 24 months
(HbA1c 7.36% versus 7.58%, mean difference -0.22%,
P = 0.022) and major hypoglycemic events (69% risk reduction,
P = 0.001) versus NPH. Patients treated with detemir gained less
weight (1.7 versus 2.7 kg, P = 0.024). Events were projected for
a time horizon of 50 years. RESULTS: Basal-bolus therapy with
insulin detemir was projected to improve mean life expectancy by
0.09 years (12.80 versus 12.71 years) versus NPH in Germany.
Similar beneﬁts were observed in the other countries
(Belgium + 0.14, France + 0.13, Italy + 0.15 and Spain + 0.07
years). The time to onset of any diabetes-related complication
was delayed by 0.08 years in the detemir arm (1.18 versus 1.10
years). Time to onset and cumulative incidence (CI) of diabetic
eye and renal disease, neuropathy and amputations were gener-
ally decreased for detemir-based therapy, with greatest beneﬁts
observed in renal disease. The CIs of heart failure, angina and
stroke were slightly raised in the detemir-based treatment arm as
overall survival was increased, exposing these patients to a longer
ongoing risk of these events. CONCLUSIONS: The modelling
analysis suggests that insulin detemir is likely to improve life
expectancy, delay the onset of and reduce the cumulative inci-
dence of most diabetes related complications in type 1 diabetes
patients.
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IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM
INSULIN NPHTO INSULIN GLARGINE:A RETROSPECTIVE
OBSERVATIONAL STUDY
Gordon JP1, Sharplin P1, Peters J2,Tetlow AP1, Longman AJ1,
McEwan P1
1Cardiff Research Consortium, Cardiff, UK, 2Cardiff University, Cardiff,
UK
OBJECTIVES: This study investigated the effect on glycaemic
control of switching from a NPH-based regimen to a glargine-
based regimen in 701 patients with type 1 (T1) (n = 304) or type
2 (T2) (n = 397) diabetes, using unselected primary care data.
METHODS: Data for this retrospective observational study were
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